MicroRNA 3926-1 (MIR3926-1)

MicroRNA 3926-1 is a member of the microRNA family, which are short (20–24 nucleotide), non-coding RNA molecules that regulate gene expression by binding to complementary sequences in mRNA transcripts, resulting in gene silencing typically through translational repression or target degradation[3]. MicroRNAs are crucial in a wide range of biological processes including development, differentiation, proliferation, and apoptosis[1][3][4]. However, there is currently a lack of specific literature or consensus on microRNA 3926-1 itself regarding its biological function, disease associations, or relevance as a drug target. There is no evidence that MIR3926-1 is a validated therapeutic target (e.g., receptor, enzyme, transporter, etc.)[3]. There is no published data indicating its use in patient selection, drug targeting, or disease biomarker panels[3]. The gene entry exists (GeneCards) but lacks further detail on biological role, disease linkage, or safety profile, suggesting it may be uncharacterized or not clinically relevant at present[3]. Therefore, this target appears incorrect for therapeutic targeting in current scientific databases, as no mechanisms of action, approved drugs, or disease associations are reported. This information reflects current knowledge—with the status that MIR3926-1 is a microRNA gene (non-coding RNA), not an established receptor, enzyme, transporter, or actionable therapeutic target[3].

Other names

hsa-mir-3926-1mir-3926-1MIR3926-1